JPH01246208A - External use preparation for skin - Google Patents

External use preparation for skin

Info

Publication number
JPH01246208A
JPH01246208A JP63074217A JP7421788A JPH01246208A JP H01246208 A JPH01246208 A JP H01246208A JP 63074217 A JP63074217 A JP 63074217A JP 7421788 A JP7421788 A JP 7421788A JP H01246208 A JPH01246208 A JP H01246208A
Authority
JP
Japan
Prior art keywords
skin
extract
thymus
vitamins
deproteinized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP63074217A
Other languages
Japanese (ja)
Inventor
Yoshiko Sato
嘉子 佐藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiseido Co Ltd
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Priority to JP63074217A priority Critical patent/JPH01246208A/en
Publication of JPH01246208A publication Critical patent/JPH01246208A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Zoology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PURPOSE:To obtain external preparation for skin which has effects of preventing skins from being aged, because of its excellent effect of improving skin roughness, softening horny skins, turn over accelerating effect and wound healing acceleration, by using protein-removed thymus extract and vitamins. CONSTITUTION:The external preparation for skin contains 0.0001-5.0wt.% of proteinremoved thymus extract obtained from animal thymus and 0.0001-5.0wt.% of vitamins. The protein-removed extract is obtained by defatting thymuses from animals with ether, combining with a buffer solution of 6.8-7.9pH, hydrolyzing with an organic acid of 3 or lower pH and extracting and adding protease to the residue. The preparation for skin can contain the above-stated essential component as well as other components used usually and is used in the forms of cosmetic lotion, emulsion, cream or ointment.

Description

【発明の詳細な説明】 [産業上の利用分野] 本発明は除蛋白胸腺抽出物と、ビタミン類の一種あるい
は二種以上とを配合することを特徴としてなる、肌荒れ
改善効果、角質改善効果、ターンオーバー速度促進効果
、創傷治癒促進効果に優れ、皮膚の老化を防止する効果
を有する皮膚外用剤に関する。
[Detailed Description of the Invention] [Industrial Field of Application] The present invention is characterized by blending a deproteinized thymus extract with one or more vitamins, which has an effect on improving rough skin, an effect on improving keratin, The present invention relates to a skin preparation for external use that has excellent turnover rate promoting effects, wound healing promoting effects, and prevents skin aging.

[従来の技術] 荒れた肌は、乾燥して皮膚内の水分量が減少するととも
に角質細胞の機能が低下することなどによっておこる。
[Prior Art] Rough skin is caused by dryness, a decrease in the amount of moisture in the skin, and a decline in the function of corneocytes.

特に冬期の空気が乾燥した時に悪化しやすく、このよう
な状態を改善する為には、皮膚のターンオーバーを高め
るとともに、皮膚機能を正常に維持することが必要であ
り、各種の薬剤が開発されてきた。
It tends to worsen especially when the air is dry in winter, and to improve this condition, it is necessary to increase skin turnover and maintain normal skin function, and various drugs have been developed. It's here.

従来の方法としては、皮膚表面に皮脂類似組成物あるい
は保湿剤を塗布し、皮膚を被うことにより乾燥を防止し
たり、ビタミンE剤等により皮膚の血行を促進きせる方
法がとられてきたが、その効果はいまだ十分ではなく、
効果を期待するには、およばなかった。
Conventional methods include applying sebum-like compositions or moisturizers to the skin surface and covering the skin to prevent dryness, and using vitamin E preparations to promote blood circulation in the skin. , its effect is still not sufficient,
The effect was not what I expected.

[発明が解決しようとする問題点] 本発明者らは、肌荒れ防止、肌荒れ改善効果を高め皮膚
の老化を防止する方法はないものかと鋭意研究した結果
、除蛋白胸腺抽出物とビタミン類の一種あるいは二種以
上とを併用することによって皮膚のターンオーバーを早
める作用が有ることを見出し、このことに着目して研究
した結果、除蛋白胸腺抽出物とビタミン類の一種あるい
は二種以上とを配合した皮膚外用剤を経皮的に投与した
場合、創傷治癒、肌荒れ防止、肌荒れ改善、老化防止の
効果に優れていることを見出し、本発明を完成するに至
った。
[Problems to be Solved by the Invention] As a result of intensive research into a method to prevent skin aging by enhancing the effect of preventing and improving skin roughness, the present inventors found that a deproteinized thymus extract and a type of vitamin Alternatively, we found that the combination of two or more types has the effect of accelerating skin turnover, and as a result of research focusing on this, we combined deproteinized thymus extract and one or more vitamins. The present inventors have discovered that when administered transdermally, this external skin preparation has excellent effects on wound healing, prevention of rough skin, improvement of rough skin, and prevention of aging, and has led to the completion of the present invention.

[問題点を解決するための手段] すなわち本発明は、除蛋白胸腺抽出物と、ビタミン類の
一種あるいは二種以上とを含有することを特徴とする皮
膚外用剤である。
[Means for Solving the Problems] That is, the present invention is an external skin preparation characterized by containing a deproteinized thymus extract and one or more vitamins.

以下、本発明の構成について詳述する。Hereinafter, the configuration of the present invention will be explained in detail.

本発明に用いられる除蛋白胸腺抽出物は、例えば以下の
方法で得られる。
The deproteinized thymus extract used in the present invention can be obtained, for example, by the following method.

動物由来の胸腺を細分もしくは均質化した後、−15℃
で脱脂を行ない、エーテル処理後、pH6,8〜7.9
の緩衝液を加え、更にpH3以下の有機酸を加えて分解
、抽出後、残渣にプロテアーゼを加え、粗エキスを得る
。この粗エキスを透析により除蛋白部と蛋白含有部とに
分離し、後者は濃縮又は凍結乾燥後、酵素によりベブタ
イド分画に至るまで加水分解し、酸・エタノール沈澱に
より残渣蛋白を除去し、先の除蛋白部と合わせ真空中で
1士しい乾燥残分含量になるまで濃縮し、pH7前後に
調節後無菌濾過して得られる。
-15°C after mincing or homogenizing the animal-derived thymus
After degreasing with ether and treating with ether, pH 6.8-7.9
After adding a buffer solution and further adding an organic acid having a pH of 3 or less for decomposition and extraction, protease is added to the residue to obtain a crude extract. This crude extract is separated into a protein-free part and a protein-containing part by dialysis, and the latter is concentrated or freeze-dried, then hydrolyzed with enzymes to the bebutide fraction, residual protein is removed by acid/ethanol precipitation, and It is obtained by combining with the protein-removed portion of the product and concentrating in vacuo to a desired dry residue content, adjusting the pH to around 7, and then sterile filtration.

本発明に用いられる除蛋白胸腺抽出物の配合量は、皮膚
外用剤全量中乾燥固形分として0.0001〜5.0重
量%である。
The amount of deproteinized thymus extract used in the present invention is 0.0001 to 5.0% by weight as a dry solid content in the total amount of the skin external preparation.

本発明においては、上記除蛋白胸腺抽出物に加えて、ビ
タミン類の一種あるいは二種以上を配合する。
In the present invention, in addition to the above deproteinized thymus extract, one or more vitamins are blended.

本発明で用いられるビタミン類は、ビタミンへ油、レヂ
ノール、酢酸レチノール等のビタミンA類、リボフラビ
ン、酪酸リボフラビン、フラビンアデニンジヌクレオチ
ド等のビタミン82類、ピリドキシン塩酸塩、ビリドキ
シンジオクタノエート等のビタミン86類、L−アスコ
ルビン酸、L−アスコルビン酸シバルミチン酸エステル
、L−アスコルビン酸−2−硫酸Na等のビタミンC類
、パントテン酸カルシウム、D−バントテニルアルコー
ル、バントテニルエチルエーテル、アセデルバントテニ
ルエチルエーテル等のパントテン酸類、エルゴカルシフ
ェロール、コレカルシフェロール等のビタミンD類、ニ
コチン酸、ニコチン酸アミド、ニコチン酸ベンジル等の
ニコチン酸類、α−トコフェロール、酢酸トコフェロー
ル、ニコチンMDL−α−トコフェロール、コハク酸D
L−α−トコフェロール等のビタミンE類、ビタミンP
1ビオチン等がある。
The vitamins used in the present invention include vitamin A such as vitamin oil, redinol, and retinol acetate, 82 vitamins such as riboflavin, riboflavin butyrate, and flavin adenine dinucleotide, and pyridoxine hydrochloride and pyridoxine dioctanoate. 86 vitamins, L-ascorbic acid, L-ascorbic acid cibalmitic acid ester, vitamin C such as L-ascorbic acid-2-sodium sulfate, calcium pantothenate, D-bantothenyl alcohol, bantothenyl ethyl ether, acederbant Pantothenic acids such as thenyl ethyl ether, vitamin Ds such as ergocalciferol and cholecalciferol, nicotinic acids such as nicotinic acid, nicotinamide, and benzyl nicotinate, α-tocopherol, tocopherol acetate, nicotine MDL-α-tocopherol, Succinic acid D
Vitamin E such as L-α-tocopherol, vitamin P
1 biotin, etc.

ビタミン類の配合量は、皮膚外用剤全量中の0゜000
1〜5.0重量%である。
The amount of vitamins added is 0゜000 of the total amount of the skin external preparation.
It is 1 to 5.0% by weight.

除蛋白胸腺抽出物あるいはビタミンAの一種あるいは二
種以上の配合量が0.0001重景%未満ではその効果
が乏しくなる傾向があり、逆に5.0重量%を越えて配
合しても効果の大きな増大は望むことは出来ない。
If the amount of deproteinized thymus extract or one or more types of vitamin A is less than 0.0001% by weight, the effect tends to be poor, and conversely, if the amount is more than 5.0% by weight, it will be effective. We cannot hope for a large increase in .

本発明の皮膚外用剤には上記した必須成分の他に通常化
粧品や医薬品等の皮膚外用剤に用いられる他の成分、例
えばアボガド油、パーム油、ビーナツツ油、牛脂、コメ
ヌカ油、ホホバ油、月見草油、カルナバロウ、ラノリン
、流動パラフィン、スクワラン、バルミチン酸イソステ
アリル、イソステアリルアルコール、トリー2−エチル
へキサン酸グリセリン等の油分、グリセリン、ソルビト
ール、ポリエチレングリコール、バチルアルコール、コ
ラーゲン、ヒアルロン酸、コンドロイチン硫酸、デキス
トラン硫酸ナトリウム等の保湿剤、バラジメチルアミノ
安息香酸アミル、2−ヒドロキシ−4−メトキシベンゾ
フェノン−5−スルホンMNa。
In addition to the above-mentioned essential ingredients, the external skin preparation of the present invention contains other ingredients commonly used in external skin preparations such as cosmetics and pharmaceuticals, such as avocado oil, palm oil, peanut oil, beef tallow, rice bran oil, jojoba oil, and evening primrose. Oil, carnauba wax, lanolin, liquid paraffin, squalane, isostearyl valmitate, isostearyl alcohol, glycerin tri-2-ethylhexanoate, glycerin, sorbitol, polyethylene glycol, batyl alcohol, collagen, hyaluronic acid, chondroitin sulfate, Humectants such as dextran sodium sulfate, amyl valadimethylaminobenzoate, 2-hydroxy-4-methoxybenzophenone-5-sulfone MNa.

ウロカニン酸、ジイソブロビルケイヒ酸エチル等の紫外
線吸収剤、エリソルビン酸ナトリウム、パラヒドロキシ
アニソール等の酸化防止層、ステアリル硫酸ナトリウム
、セチル硫酸ジェタノールアミン、セチルトリメチルア
ンモニウムサッカリン、イソステアリン酸ポリエチレン
グリコール、アラキン酸グリセリル、ジグリセリンジイ
ソステアレート等の界面活性剤、エチルパラベン、ブチ
ルパラベン等の防腐剤、グリチルリチン酸誘導体、グリ
チルレチン酸誘導体、サリチル酸誘導体、ヒノキチオー
ル、酸化亜鉛、アラントイン等の消炎剤、胎盤抽出物、
グルタチオン、ユキノシタ抽出物等の美白剤、オウバク
、オウレン、シコン、シャクヤク、センブリ、バーチ、
セージ、ビワ、ニンジン、アロエ、ゼニアオイ、アイリ
ス、ブドウ、ヨクイニン、ヘチマ、ユリ、サフラン、セ
ンキュウ、シフウキヨウ、オトギリソウ、オノニス、ロ
ーズマリー、ニンニク等のf[tl 出物、ローヤルビ
リー、感光素、コレステロール語導体、各狸アミノ酸類
、牌臓抽出物、幼生血抽出物等の賦活剤、γ−オリザノ
ール等の血行促進剤、硫黄、チアントール等の抗脂漏剤
、カルボキシビニルポリマー、カリボキシメチルセルロ
ース、カルボキシヒト・ロキシプロビルセルロース等の
増粘剤、香料、水、アルコール、チタンイエロー、カー
サミン、ベニバナ赤等の色剤、ポリエチレン、ナイロン
等の樹脂粉末等を必要に応じて適宜配合することかでき
る。
UV absorbers such as urocanic acid, ethyl diisobrobyl cinnamate, antioxidant layers such as sodium erythorbate and parahydroxyanisole, sodium stearyl sulfate, jetanolamine cetyl sulfate, cetyl trimethylammonium saccharin, polyethylene glycol isostearate, arachidic acid Surfactants such as glyceryl and diglycerine diisostearate, preservatives such as ethylparaben and butylparaben, glycyrrhizic acid derivatives, glycyrrhetinic acid derivatives, salicylic acid derivatives, anti-inflammatory agents such as hinokitiol, zinc oxide, allantoin, placenta extract,
Glutathione, whitening agents such as saxifrage extract, sagebrush, orensis, chicon, peony, japonica, birch,
Sage, loquat, carrot, aloe, mallow, iris, grape, Japanese lily, loofah, lily, saffron, nebula, perforatum, rosemary, garlic, etc., royal billy, photosensitizer, cholesterol word Conductors, various raccoon amino acids, activators such as spleen extract and larval blood extract, blood circulation promoters such as γ-oryzanol, antiseborrheic agents such as sulfur and thianthol, carboxyvinyl polymer, carboxymethylcellulose, carboxyhuman - Thickeners such as roxyprovir cellulose, fragrances, water, alcohol, coloring agents such as titanium yellow, casamine, safflower red, resin powders such as polyethylene and nylon, etc. can be appropriately blended as necessary.

また本発明の皮膚外用剤の剤型は任意であり、例えば化
粧水等の可溶化系、乳液、クリーム等の乳化系あるいは
軟膏、分散液などの剤型をとることができる。
Further, the dosage form of the skin external preparation of the present invention is arbitrary, and may be, for example, a solubilized system such as a lotion, an emulsified system such as a milky lotion or a cream, or a dosage form such as an ointment or a dispersion.

[発明の効果コ (ヒト皮膚による肌荒れ改善効果試験)実施例1で得た
化粧水とブランク化粧水(除蛋白胸腺抽出物及び酢酸ト
コフェロールを配合しないもの)を用いて人体パネルで
肌荒れ改善効果試験を行った。
[Effects of the Invention (Skin improvement effect test on human skin) Skin roughness improvement effect test on human body panel using the lotion obtained in Example 1 and blank lotion (not containing deproteinized thymus extract and tocopherol acetate) I did it.

すなわち、女性健常人(顔面)の皮膚表面形態をミリス
ン樹脂によるレプリカ法を用いて肌のレプリカを取り題
?jlifm(17倍)にてH察する。皮紋の状態及び
角層のllJm状態から表−2に示す基準に基づいて肌
荒れ評価1.2と判断された者(肌あれパネル)25名
を用い、顔面左右半々に、実施例1で得た化粧水とブラ
ンク化粧水を1日1回2週間塗布した。
In other words, the topic is to create a skin replica of the skin surface morphology of a healthy female person (facial) using the replica method using Millisne resin. Observe H using jlifm (17x magnification). Using 25 people (rough skin panel) who were judged to have a skin roughness rating of 1.2 based on the condition of the skin pattern and the llJm condition of the stratum corneum based on the criteria shown in Table 2, the test sample obtained in Example 1 was applied to the left and right half of the face. A blank lotion and a blank lotion were applied once a day for two weeks.

2週間後、再び上述のレプリカ法にて肌の状態を観察し
、表−1の判定基準に従って評価した。
Two weeks later, the skin condition was observed again using the replica method described above and evaluated according to the criteria in Table 1.

(以下余白) 表−1 結果を表−2に示す。(Margin below) Table-1 The results are shown in Table-2.

表−2 この結果より、除蛋白胸腺抽出物及び酢酸トコフェロー
ル配合の化粧水を使用した顔面部位はブランク化粧水を
使用した顔面部位と比較し、顕著な肌荒れ改善効果が認
められた。
Table 2 From the results, it was found that the facial area treated with the lotion containing deproteinized thymus extract and tocopherol acetate had a remarkable effect on improving rough skin compared to the facial area treated with the blank lotion.

[実施例] 次に実施例により本発明をざらに詳細に説明する。尚、
本発明はこれにより限定されるものではない。配合量は
重量%である。
[Example] Next, the present invention will be explained in detail with reference to Examples. still,
The present invention is not limited thereby. The blending amount is in weight%.

実施例 1    化粧水 (1)除蛋白胸腺抽出物      0.05(2)酢
酸トコフェロール     0.01(3)グリセリン
         4.0(4)1.3−ブチレングリ
コール 4.0(5)エタノール         7
.0(6)ポリオキシエチレン オレイルアルコール 0.5 (7)メチルパラベン       0.05(8)ク
エン酸           0.05(9)クエン酸
ソーダ       0.1(10)香料      
      0.05(11)精製水        
   残余(製法) 精製水にクエン酸、クエン酸ソーダ、グリセリン、1.
3−ブチレングリコール、除蛋白胸腺抽出物を溶解する
。別にエタノールにポリオキシエヂレンオレイルアルコ
ール、酢酸トコフェロール、香料、メチルパラベンを溶
解し、これを前述の精製水溶液に加えて可溶化し、濾過
して化粧水を得た。
Example 1 Lotion (1) Deproteinized thymus extract 0.05 (2) Tocopherol acetate 0.01 (3) Glycerin 4.0 (4) 1.3-butylene glycol 4.0 (5) Ethanol 7
.. 0 (6) Polyoxyethylene oleyl alcohol 0.5 (7) Methylparaben 0.05 (8) Citric acid 0.05 (9) Sodium citrate 0.1 (10) Fragrance
0.05 (11) Purified water
Residue (manufacturing method) Citric acid, sodium citrate, glycerin, purified water, 1.
3-Butylene glycol, dissolve the deproteinized thymus extract. Separately, polyoxyethylene oleyl alcohol, tocopherol acetate, fragrance, and methylparaben were dissolved in ethanol, and this was added to the above-mentioned purified aqueous solution to solubilize and filtered to obtain a lotion.

(除蛋白胸腺抽出物の製法) 子牛の胸腺を冷凍細分化し、アセトン501を加え48
時間放置し、序アセトン251を加え72時間放置し、
脂溶性部分を除去する。アセトン層を分離後、残留物に
エチルエーテル15L及び精製水5〜101を加え、−
15℃〜−25℃で100時間以上放置後、遠心分離を
行なう。残留物に緩衝液を加えて中性で2回分離抽出を
行ない(a、b)、残留物にクエン酸サイクルの酸1〜
8駕、並びに0.001〜0.01%の亜鉛を含む溶液
を加え、pH3以下で2回抽出する(c、d)。
(Production method of protein-depleted thymus extract) Frozen calf thymus was cut into pieces, and acetone 501 was added to the
Leave it for an hour, add acetone 251 and leave it for 72 hours.
Remove fat-soluble parts. After separating the acetone layer, 15 L of ethyl ether and 5 to 10 liters of purified water were added to the residue, and -
After standing at 15°C to -25°C for 100 hours or more, centrifugation is performed. Add a buffer solution to the residue and perform separation and extraction twice in neutral conditions (a, b).
Add a solution containing 0.001% to 0.01% zinc and extract twice at pH 3 or lower (c, d).

残留物にプロテアーゼを加え48時間以上反応させ、更
にアルドン酸を加えて除蛋白する。更に、1〜2時間達
心分離した抽出物(e)と先に得られた抽出物a ”−
dを合わせ、パラベンを添加しpf(7,0に:A整し
た後、透析を行なう。その後無菌濾過し4℃で貯蔵する
(f)。蛋白含有部については冷凍乾燥ご酵素で加水分
解し除蛋白を行ない、遠心分離後、得られた除蛋白抽出
物gを、先の除蛋白抽出物fと合わせ濃縮し、防腐剤を
加え、PH調整後約10zの乾燥固型物を含有するまで
濃縮することにより得られる。
Protease is added to the residue and reacted for 48 hours or more, and aldonic acid is further added to remove protein. Furthermore, the extract (e) separated for 1 to 2 hours and the previously obtained extract a''-
Combine d and add paraben to adjust pf (7.0:A), and then perform dialysis. After that, sterile filter and store at 4°C (f). Protein-containing parts are hydrolyzed with freeze-dried enzymes. After deproteinization and centrifugation, the resulting deproteinized extract g is concentrated with the previously deproteinized extract f, a preservative is added, and after pH adjustment, the mixture is concentrated until it contains dry solids of about 10z. Obtained by concentrating.

実施例 2    クリーム (1)セトステアリルアルコール   3.5(2)ス
クワラン          40.0(3)ミツロウ
           3.0(4)還元ラノリン  
       5.0(5)エチルパラベン     
   0.3(6)ポリオキシエチレン(20) ソルビタンモノパルミチン酸 エステル           2.0(7)ステアリ
ン酸モノグリセリド  2.0(8)除蛋白胸腺抽出物
       0.5実施例1記載の抽出物 (9)酢酸レチノール        2.0(10)
肝臓抽出物          0.01(11)月見
草油           0.05(12)香料  
           0.03(13)1.3−ブチ
レングリコール  5.0(14)グリセリン    
     5.0(15)精製水          
  残余(製法) (1) (2) (3) (4) (5) (6) (
7)と(11) (12)を加熱溶解し75℃に加温し
た(8) (9) (10) (13) (14)と(
15)に攪拌しながら加える。ホモミキサー処理し乳化
粒子を細かくした後、攪拌しながら急冷し、クリームを
1また。
Example 2 Cream (1) Cetostearyl alcohol 3.5 (2) Squalane 40.0 (3) Beeswax 3.0 (4) Reduced lanolin
5.0(5) Ethylparaben
0.3 (6) Polyoxyethylene (20) Sorbitan monopalmitate ester 2.0 (7) Stearic acid monoglyceride 2.0 (8) Deproteinized thymus extract 0.5 Extract described in Example 1 (9) Retinol acetate 2.0 (10)
Liver extract 0.01 (11) Evening primrose oil 0.05 (12) Flavoring
0.03(13) 1.3-butylene glycol 5.0(14) Glycerin
5.0 (15) Purified water
Residue (manufacturing method) (1) (2) (3) (4) (5) (6) (
7), (11), and (12) were dissolved by heating and heated to 75°C. (8), (9), (10), (13), (14),
Add to 15) while stirring. After processing with a homomixer to make the emulsified particles fine, it is rapidly cooled while stirring, and the cream is added once again.

実施例 3    乳液 (1)除蛋白胸腺抽出物       0.01実施例
1記載の抽出物 (2)L−アスコルビン酸−2−硫酸Na   O,0
05(3)ステアリン酸          1.5(
4)セヂルアルコール       0.5(5)ミツ
ロウ            2.0(6)ポリオキシ
エチレン(10) モノオレイン酸エステル   1.0 (7)クインスシード抽出物 (5%水溶液)    20.0 (8)ヒアルロン酸Ha         O,1(9
)胎盤抽出物          0.05(10)プ
ロピレングリコール      5.0(11)エタノ
ール          3.0(12)エチルパラベ
ン        0.3(13)香11      
       0.03(14)精製水       
      残余(製法) エタノールに香料を加えて溶解する(アルコール相)。
Example 3 Emulsion (1) Deproteinized thymus extract 0.01 Extract described in Example 1 (2) L-ascorbic acid-2-sulfate Na O,0
05(3) Stearic acid 1.5(
4) Seedyl alcohol 0.5 (5) Beeswax 2.0 (6) Polyoxyethylene (10) Monooleic acid ester 1.0 (7) Quince seed extract (5% aqueous solution) 20.0 (8) Hyaluron Acid Ha O,1(9
) Placenta extract 0.05 (10) Propylene glycol 5.0 (11) Ethanol 3.0 (12) Ethylparaben 0.3 (13) Fragrance 11
0.03 (14) Purified water
Residue (manufacturing method) Add fragrance to ethanol and dissolve (alcohol phase).

精製水にプロピレングリコール、ヒアルロン酸Haを加
えて加熱溶解して70℃に保つ(水相)。クイスシード
抽出物を除く他の成分を混合し、加熱溶解して70℃に
保つ(油相)。水相に油イ目を加えて予備乳化を行ない
、ホモミキサーで均一に乳化する。これを攪拌しながら
アルコール相とクインスシード抽出物を加える。その後
攪拌しながら30℃に冷却して乳液を得た。
Propylene glycol and hyaluronic acid Ha are added to purified water, dissolved by heating, and kept at 70°C (aqueous phase). The other ingredients except the Kuisseed extract are mixed, heated and dissolved and kept at 70°C (oil phase). Pre-emulsify by adding oil to the aqueous phase, and homogeneously emulsify using a homomixer. Add the alcohol phase and quince seed extract while stirring. Thereafter, the mixture was cooled to 30° C. while stirring to obtain a milky lotion.

実施例 4   パック (1)除蛋白胸腺抽出物      0.05実施例1
記載の抽出物 (2)コレカルシフェロール    0.01(3)ポ
リビニルアルコール   15.0(4)ポリエチレン
グリコール   3.0(5)プロピレングリコール 
   7.0(6)エタノール        10.
0(7)メチルパラベン       0.05(8)
香1EI             0.05(9)精
製水           残余(製法) 精製水にポリエチレングリコール、プロピレングリコー
ル、メチルパラベン、除蛋白胸腺抽出物及びコレカルシ
フエa−ルを加え攪拌溶解する。
Example 4 Pack (1) Deproteinized thymus extract 0.05 Example 1
Extract as described (2) Cholecalciferol 0.01 (3) Polyvinyl alcohol 15.0 (4) Polyethylene glycol 3.0 (5) Propylene glycol
7.0 (6) Ethanol 10.
0(7) Methylparaben 0.05(8)
Fragrance 1EI 0.05 (9) Purified water Remaining (manufacturing method) Add polyethylene glycol, propylene glycol, methyl paraben, deproteinized thymus extract, and cholecalcifera to purified water and dissolve with stirring.

つぎにポリビニルアルコールを加え沈黙攪拌し、香t1
を溶解したエタノールを加えI!拌溶解してパックを得
た。
Next, add polyvinyl alcohol and stir silently.
Add ethanol dissolved in I! A pack was obtained by stirring and dissolving.

実施例 6   軟膏 (1)除蛋白胸腺抽出物      0.5実施例1記
戦の抽出物 (2)酢酸トコフェロール     1.0(3)パル
ミチン酸レゾノール   0.5(4)ステアリルアル
コール   18.0(5)モクロウ        
  20.0(6)ポリオキシエチレン(10) モノオレイン酸エステル   0.25(7)グリセリ
ンモノ ステアリン酸エステル    0.3 (8)ワセリン          40.0(9)精
製水           残余(製法) 精製水を70℃に保ち(水相)以下の成分を70℃にて
混合溶解する(油I■)。水相に油相を加え、ホモミキ
サーで均一に乳化後冷却して軟膏を得た。
Example 6 Ointment (1) Deproteinized thymus extract 0.5 Example 1 Extract of the war (2) Tocopherol acetate 1.0 (3) Resonol palmitate 0.5 (4) Stearyl alcohol 18.0 (5 ) Mokuro
20.0 (6) Polyoxyethylene (10) Monooleate 0.25 (7) Glycerin monostearate 0.3 (8) Vaseline 40.0 (9) Purified water Remaining (manufacturing method) Purified water 70 Keep the temperature at 70°C (aqueous phase) and mix and dissolve the following ingredients at 70°C (oil I■). The oil phase was added to the water phase, uniformly emulsified using a homomixer, and then cooled to obtain an ointment.

特許出願人   株式会社  資生堂Patent applicant: Shiseido Co., Ltd.

Claims (1)

【特許請求の範囲】[Claims] 1、除蛋白胸腺抽出物と、ビタミン類の一種あるいは二
種以上とを含有することを特徴とする皮膚外用剤。
1. A skin preparation for external use, characterized by containing a deproteinized thymus extract and one or more vitamins.
JP63074217A 1988-03-28 1988-03-28 External use preparation for skin Pending JPH01246208A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP63074217A JPH01246208A (en) 1988-03-28 1988-03-28 External use preparation for skin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63074217A JPH01246208A (en) 1988-03-28 1988-03-28 External use preparation for skin

Publications (1)

Publication Number Publication Date
JPH01246208A true JPH01246208A (en) 1989-10-02

Family

ID=13540802

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63074217A Pending JPH01246208A (en) 1988-03-28 1988-03-28 External use preparation for skin

Country Status (1)

Country Link
JP (1) JPH01246208A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001074A1 (en) * 1992-07-13 1994-01-20 Shiseido Company, Ltd. Composition for dermatologic preparation
US5686086A (en) * 1992-07-13 1997-11-11 Shiseido Co., Ltd. External skin treatment composition
US5798109A (en) * 1992-07-13 1998-08-25 Shiseido Company, Ltd. External skin treatment composition
US5962000A (en) * 1992-07-13 1999-10-05 Shiseido Company, Ltd. External skin treatment composition
JP2003095961A (en) * 2001-09-27 2003-04-03 Combi Corp Skin beautifying promoter

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001074A1 (en) * 1992-07-13 1994-01-20 Shiseido Company, Ltd. Composition for dermatologic preparation
US5484816A (en) * 1992-07-13 1996-01-16 Shiseido Company, Ltd. External skin treatment composition
US5686086A (en) * 1992-07-13 1997-11-11 Shiseido Co., Ltd. External skin treatment composition
US5798109A (en) * 1992-07-13 1998-08-25 Shiseido Company, Ltd. External skin treatment composition
US5962000A (en) * 1992-07-13 1999-10-05 Shiseido Company, Ltd. External skin treatment composition
US6024941A (en) * 1992-07-13 2000-02-15 Shiseido Company, Ltd. External skin treatment composition
KR100295030B1 (en) * 1992-07-13 2001-09-17 겜마 아키라 Skin external composition
JP2003095961A (en) * 2001-09-27 2003-04-03 Combi Corp Skin beautifying promoter

Similar Documents

Publication Publication Date Title
EP0601698B1 (en) Topical composition comprising tocopherol
JPH05262636A (en) Dermatic external preparation for body
JP2000229832A (en) Skin lotion
JPH0873342A (en) Skin external preparation or bathing agent containing rubi fructus extract
JP2003055190A (en) Collagenase inhibitor and anti-ageing cosmetic
JP2001081008A (en) Skin preparation for external use keeping and improving the skin from chapping
JPS5916816A (en) Composition for external use
JP2002003358A (en) Skin care preparation
JPS6379809A (en) Skin drug for external use
JP3263409B2 (en) External preparation for skin
JPH01246208A (en) External use preparation for skin
JPH0782131A (en) Hyaluronidase activity inhibitor and oil in water type cream base preparation
US5776438A (en) External preparation
JPS61205204A (en) External preparation for skin
JP3140876B2 (en) Melanin production inhibitor and external preparation for skin
JPH10279418A (en) Preparation for external use for skin
JP3076620B2 (en) External preparation for skin
JPH11171784A (en) External preparation for skin
JP2000063226A (en) Skin preparation for external use
JPH10203921A (en) Skin preparation for external use
JPS61254510A (en) External agent for skin
JP2895525B2 (en) External preparation for skin
DE1667890B2 (en) DERMATOLOGICAL AND COSMETIC EXTERNAL PRODUCTS FOR THE TREATMENT OF SKIN COLLAGENOSE
JPH0210122B2 (en)
JPH0436137B2 (en)